Trademark: 90295383
Status Date
Tuesday, December 19, 2023
Filing Date
Tuesday, November 3, 2020
Published for Opposition
Tuesday, May 18, 2021
5 Pharmaceuticals for the treatment of agitation, namely, an orally-dissolving formulation used for the treatment of agitation associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders, namely, schizophrenia, bipolar disorder, dementia, and depression
Dec 21, 2023
Notice Of Approval Of Extension Request E-Mailed
Dec 19, 2023
Sou Extension 4 Granted
Dec 19, 2023
Sou Extension 4 Filed
Dec 19, 2023
Sou Teas Extension Received
Jun 14, 2023
Notice Of Approval Of Extension Request E-Mailed
Jun 12, 2023
Sou Extension 3 Granted
Jun 12, 2023
Sou Extension 3 Filed
Jun 12, 2023
Sou Teas Extension Received
Dec 8, 2022
Notice Of Approval Of Extension Request E-Mailed
Dec 6, 2022
Sou Extension 2 Granted
Dec 6, 2022
Sou Extension 2 Filed
Dec 6, 2022
Sou Teas Extension Received
Jun 2, 2022
Notice Of Approval Of Extension Request E-Mailed
May 31, 2022
Sou Extension 1 Granted
May 31, 2022
Sou Extension 1 Filed
May 31, 2022
Sou Teas Extension Received
Dec 28, 2021
Noa E-Mailed - Sou Required From Applicant
Nov 15, 2021
Ttab Release Case To Trademarks
Nov 15, 2021
Opposition Terminated No. 999999
Nov 15, 2021
Opposition Dismissed No. 999999
Sep 15, 2021
Opposition Instituted No. 999999
Jun 15, 2021
Extension Of Time To Oppose Received
May 18, 2021
Official Gazette Publication Confirmation E-Mailed
May 18, 2021
Published For Opposition
Apr 28, 2021
Notification Of Notice Of Publication E-Mailed
Apr 9, 2021
Approved For Pub - Principal Register
Apr 8, 2021
Assigned To Examiner
Dec 31, 2020
New Application Office Supplied Data Entered
Nov 6, 2020
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
